Page last updated: 2024-11-06

3,4-dihydroxyphenylglycol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-dihydroxyphenylglycol, also known as DOPET, is a catecholamine metabolite formed during the breakdown of dopamine. It is of interest to researchers studying Parkinson's disease, as it is a potential biomarker for the disease and can be measured in urine and cerebrospinal fluid. It is also a precursor to the neurotransmitter norepinephrine, and its synthesis involves the enzyme dopamine beta-hydroxylase. Studies have shown that levels of DOPET may be altered in individuals with Parkinson's disease, and its measurement may be useful in monitoring disease progression and treatment effectiveness. DOPET has also been studied for its potential role in other neurological disorders, such as Alzheimer's disease and depression.'

3,4-dihydroxyphenylglycol: noradrenaline metabolite in mouse brain; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,4-dihydroxyphenylethyleneglycol : A tetrol composed of ethyleneglycol having a 3,4-dihydroxyphenyl group at the 1-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID91528
CHEBI ID1387
SCHEMBL ID141609
MeSH IDM0055398

Synonyms (54)

Synonym
1-(3,4-dihydroxyphenyl)ethane-1,2-diol
3,4-dihydroxyphenylglycol
4-(1,2-dihydroxyethyl)benzene-1,2-diol
dihydroxyphenylethylene glycol
dopeg
nsc92532
nsc-92532
3,4-dihydroxyphenylethyleneglycol
3343-19-9
C05576
phenylglycol, 3,4-dihydroxy-
4740838A-79C1-450B-827D-A3B2F61834F4
28822-73-3
AKOS003368780
FT-0694582
3,4-dihydroxyphenethyl glycol
(3,4-dihydroxyphenyl)ethylene glycol
1-(3,4-dihydroxyphenyl)-1,2-ethanediol
CHEBI:1387
3,4-dihydroxyphenylethyl glycol
2-hydroxy-2-(3,4-dihydroxy)phenylethanol
beta,3,4-trihydroxy phenethyl alcohol
A819617
ba 2775
unii-ueh9k539kj
dl-3,4-dihydroxyphenylglycol
(+-)-3,4-dihydroxyphenylglycol
ueh9k539kj ,
(1)-4-(1,2-dihydroxyethyl)pyrocatechol
einecs 249-260-9
nsc 92532
4-(1,2-dihydroxyethyl)-1,2-benzenediol
rac 3,4-dihydroxyphenylethylene glycol
FT-0638811
1,2-benzenediol, 4-(1,2-dihydroxyethyl)-
SCHEMBL141609
AKOS016843225
1,2-ethanediol, 1-(3,4-dihydroxyphenyl)-, (.+/-.)-
1,2-benzenediol, 4-(1,2-dihydroxyethyl)-, (.+/-.)-
MTVWFVDWRVYDOR-UHFFFAOYSA-N
(3,4-dihydroxyphenyl)glycol
1,2-benzenediol, 4-(1,2-dihydroxyethyl)-, (-)-
HY-W010066
CS-W010782
(+/-)-3,4-dihydroxyphenylglycol
3,4-dihydroxyphenylglycol, (+/-)-
dhpg (3,4-dihydroxyphenylglycol)
3,4-dihydroxyphenylglycol, dl-
ba-2775
DTXSID20865451
EN300-1855459
Q262270
F85606
MS-22923

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pretreatment with desipramine did not alter any of the pharmacokinetic parameters of ISO."( Haemodynamics as a determinant of the pharmacokinetics of and the plasma catecholamine responses to isoprenaline.
Graefe, KH; Halbrügge, T; Ludwig, J; Vey, G; Walter, J, 1989
)
0.28
"The pharmacodynamic equipotency of 2 dose regimens (5 mg twice daily versus 10 mg once daily) of befloxatone, a new reversible and selective monoamine oxidase A (MAO-A) inhibitor, after single and multiple doses for 6 days was examined in a randomized, double-blind, three-way crossover, placebo-controlled trial of 12 healthy volunteers."( Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Allain, H; Cimarosti, I; Curet, O; Dubruc, C; Durrieu, G; Gandon, JM; Jezequel, S; le Coz, F; Patat, A; Rosenzweig, P; Zieleniuk, I, 1996
)
0.29
" Adverse events and vital signs were recorded and pharmacokinetic parameters of fluoxetine and moclobemide were determined."( Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Amrein, R; Dingemanse, J; Gieschke, R; Guentert, T; Wallnöfer, A, 1998
)
0.3
" 3,4-Dihydroxyphenylglycol, 5-hydroxyindoleacetic acid, and 3,4-dihydroxyphenylacetic acid plasma levels and serotonin uptake did not reveal a pharmacodynamic interaction."( Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Amrein, R; Dingemanse, J; Gieschke, R; Guentert, T; Wallnöfer, A, 1998
)
1.21
" Estimated pharmacokinetic parameters were CL (41."( Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.
Csajka, C; Dostert, P; Imbimbo, BP; Piccinno, A; Verotta, D, 2005
)
0.33
" The pharmacokinetic and pharmacodynamic profile of these drugs in plasma and cerebrospinal fluid (CSF) was assessed."( A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
Kielbasa, W; Pan, A; Pereira, A, 2015
)
0.63
" Pharmacokinetic and pharmacodynamic data were obtained from healthy subjects (n = 160) from 5 clinical trials."( Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
Kielbasa, W; Lobo, E, 2015
)
0.61
" In an ADHD population treated with dasotraline 4 or 8 mg/day, dasotraline was characterized by a mean apparent half-life of 47 h and plasma concentrations reached steady-state by 10 days of dosing."( Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
Hing, J; Hopkins, SC; Koblan, KS; Loebel, A; Passarell, JA; Skende, E; Sunkaraneni, S, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetic bioavailability at steady state of both dose regimens was also similar."( Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Allain, H; Cimarosti, I; Curet, O; Dubruc, C; Durrieu, G; Gandon, JM; Jezequel, S; le Coz, F; Patat, A; Rosenzweig, P; Zieleniuk, I, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" In trachea and right atria of the guinea-pig, tertatolol inhibited, in a concentration-dependent manner, the dose-response curves to isoproterenol; the relative potency of tertatolol was higher than that of propranolol."( Effects of tertatolol on post- and prejunctional beta adrenoceptors.
Herman, AG; Jordaens, FH; Laekeman, G; Majchrowicz, BB; Verbeuren, TJ; Zonnekeyn, LL, 1985
)
0.27
" The dose-response relations for exogenous noradrenaline measured in the absence or presence of 50 microM amiloride indicated that the drug acted as a reversible competitive alpha-adrenergic antagonist."( Amiloride acts as an alpha-adrenergic antagonist in the isolated rat tail artery.
Palatý, V, 1986
)
0.27
" Dose-response regression lines showed that exercise in the heat increased the slope and shifted the Tco-NE dose relation to the left."( Heat acclimation: role of norepinephrine in the anterior hypothalamus.
Christman, JV; Gisolfi, CV, 1985
)
0.27
" The dose-response curve for verapamil was bell-shaped and the activity resided in the l form."( An inhibitory effect of verapamil and diltiazem on the release of noradrenaline from ischaemic and reperfused hearts.
Nayler, WG; Sturrock, WJ, 1984
)
0.27
" Oral dosing with amiodarone has no such effect."( Sympatholytic action of intravenous amiodarone in the rat heart.
Dart, AM; Du, XJ; Esler, MD, 1995
)
0.29
" Blood pressure, heart rate, ECG, and plasma concentrations of unconjugated adrenaline and noradrenaline were not influenced after single and repeated dosing of entacapone."( COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.
Gordin, A; Heinävaara, S; Illi, A; Koulu, M; Scheinin, M; Sundberg, S, 1994
)
0.29
" Both dose regimens provided equipotent extent and duration of MAO-A inhibition at steady state, suggesting a once daily dosage should be sufficient for most patients."( Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Allain, H; Cimarosti, I; Curet, O; Dubruc, C; Durrieu, G; Gandon, JM; Jezequel, S; le Coz, F; Patat, A; Rosenzweig, P; Zieleniuk, I, 1996
)
0.29
" However, multiple dosing of moclobemide did not lead the excessive accumulation."( Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Amrein, R; Dingemanse, J; Gieschke, R; Guentert, T; Wallnöfer, A, 1998
)
0.3
" These mGluRs are functionally active on catecholamine (CA) secretion in chromaffin cells because both (1S, 3R)-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) and the specific agonist of Group I mGluRs, (S)-3,5-dihydroxyphenylglycine (DHPG), were able to stimulate the release of CAs (adrenaline and noradrenaline) in a dose-response manner."( Expression and functional properties of group I metabotropic glutamate receptors in bovine chromaffin cells.
Aránguez, I; Arce, C; Del Campo, AB; Figueroa, S; González, MP; López, E; Oset-Gasque, MJ, 2004
)
0.32
" The dose of intravenous tyramine required to raise systolic blood pressure by 30 mm Hg (PD30) increased dose-dependently with duloxetine and was significant at the end of the 120-mg/d dosage (P<0."( Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.
Bieck, PR; Black, BK; Bymaster, FP; Garland, EM; Gonzales, C; Loghin, C; Potter, WZ; Robertson, D; Vincent, S, 2004
)
0.32
" Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET."( Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Chappell, JC; Dean, RA; Detke, MJ; Eisenhofer, G; Haber, H; Iyengar, S; Knadler, MP; Lachno, DR; Lobo, ED; Mitchell, MI; Nemeroff, CB; Owens, MJ; Pangallo, B, 2014
)
0.59
"These results related dasotraline pharmacokinetics to pharmacological activity in ADHD, and support the novel concept that maintaining constant, steady-state dopamine and norepinephrine reuptake inhibition throughout a 24-h dosing interval is a novel pharmacological approach to the management of ADHD symptoms."( Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
Hing, J; Hopkins, SC; Koblan, KS; Loebel, A; Passarell, JA; Skende, E; Sunkaraneni, S, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
catecholsAny compound containing an o-diphenol component.
tetrolA polyol that contains 4 hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Tyrosine Metabolism1657
Alkaptonuria1657
Hawkinsinuria1657
Tyrosinemia Type I1657
Disulfiram Action Pathway2366
Tyrosinemia, Transient, of the Newborn1657
Dopamine beta-Hydroxylase Deficiency1657
Monoamine Oxidase-A Deficiency (MAO-A)1657
Tyrosine metabolism ( Tyrosine metabolism )2841
NAD+ + 3,4-Dihydroxy-phenyl-ethyleneglycol = NADH + 3,4-Dihydroxy-mandelaldehyde ( Tyrosine metabolism )84

Research

Studies (909)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990207 (22.77)18.7374
1990's204 (22.44)18.2507
2000's281 (30.91)29.6817
2010's196 (21.56)24.3611
2020's21 (2.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.18 (24.57)
Research Supply Index6.90 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (5.90%)5.53%
Reviews14 (1.50%)6.00%
Case Studies6 (0.64%)4.05%
Observational1 (0.11%)0.25%
Other856 (91.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]